Dr. McDermott on IMmotion150 Trial in RCC

David F. McDermott, MD
Published: Wednesday, Feb 22, 2017



David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).

IMmotion150, a phase II, open-label, randomized study of atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC, is the first large look at PD-L1 blockade with atezolizumab in patients with untreated advanced RCC, according to McDermott.

This trial address the question of whether adding VEGF blockade with bevacizumab to PD-L1 blockade with atezolizumab extends benefit. The answer seems to be, “Yes,” says McDermott, as survival outcomes did improve, particularly in the subset of patients with inflamed tumors.
 
SELECTED
LANGUAGE


David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).

IMmotion150, a phase II, open-label, randomized study of atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC, is the first large look at PD-L1 blockade with atezolizumab in patients with untreated advanced RCC, according to McDermott.

This trial address the question of whether adding VEGF blockade with bevacizumab to PD-L1 blockade with atezolizumab extends benefit. The answer seems to be, “Yes,” says McDermott, as survival outcomes did improve, particularly in the subset of patients with inflamed tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x